I hadn't seen this one. Do you or Peter have any thoughts on Stem Cell Therapeutics Patent/IP as it relates to Stanford's? SCTPF's CEO recently said that Stanford's patents are particularly broad and might even squeeze out InhibRx. He suggested that this was the reason SCTPF went with the natural ligand to CD47, however, it is unclear to me whether the MOA between the two approaches is really all that different. Any thoughts/comments would be appreciated.
Market Data 
Markets 
AI
